Actelion to host Conference Call / Audiocast following the US FDA approval of Opsumit (macitentan) for the treatment of pulmonary arterial hypertension
(Thomson Reuters ONE via COMTEX) --
Actelion Pharmaceuticals Ltd /
Actelion to host Conference Call / Audiocast following the US FDA approval of
Opsumit (macitentan) for the treatment of pulmonary arterial hypertension
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Dear member of the investment community,
Actelion Ltd will host a Conference Call / Audiocast on following the US FDA approval of Opsumit® (macitentan) for the treatment of pulmonary arterial hypertension today, on Monday, 21 October 2013, at 14.00 CET / 13.00 BST / 08.00 a.m. EST.
The company announced on the 18 October 2013 that the United States Food and Drug Administration (FDA) has approved the use of the orally available endothelin receptor antagonist Opsumit® (macitentan) 10 mg once daily for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression.
21 October 2013 14.00 hrs - 15.00 hrs Basel (CET)
13.00 hrs - 14.00 hrs UK (BST)
08.00 a.m. - 09.00 a.m. US (EST)
Conference Call Connect #:
Dial-in participants should start calling the number below 10-15 minutes before the conference is due to start.
Dial: Europe: +41 (0)44 580 00 74
UK: +44 (0)203 367 94 53
US: +1 866 907 59 23
Listen-Only with possibility to open individual lines during Q&A session. Participants will be asked for their Name and Company.
Audiocast participants should visit the Actelion website www.actelion.com 10-15 minutes before the conference is due to start.
The archived Investor Audiocast will be available for replay through http://www.actelion.com approximately 60 minutes after the call has ended.
For further information please contact:
Senior Vice President, Head of Investor Relations & Public Affairs
+41 61 565 62 62
+1 646 737 49 72
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE
Invitation PDF - http://hugin.info/131801/R/1736798/582120.pdf
[ Back To Technology News's Homepage ]